NCT04103879 - US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2020

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

High Risk Hematological MalignancyCord Blood Transplant

Interventions

BIOLOGICAL

ECT-001-CB (UM171-Expanded Cord Blood Transplant)

"Conditioning: High dose TBI (1320 cGy TBI + Fludarabine 75 mg/m2 + Cyclophosphamide 120 mg/kg) or Intermediate Intensity regimen (400 cGy TBI + Fludarabine 150 mg/m2 + Cyclophosphamide 50 mg/kg + Thiotepa 10 mg/kg).~Single UM171-Expanded CB transplant (CD34+: 2.5-50x10E5/kg, CD3+\>1x10E6/kg)~Immunosuppression: Tacrolimus/MMF"

Trial Locations (3)

3015

Erasmus Medical Center, Rotterdam

80045

University of Colorado School of Medicine. Anschutz Medical Campus, Aurora

98109

Fred Hutchinson / University of Washington Cancer Consortium, Seattle